Hims & Hers Health Inc. (NYSE:HIMS) said it is broadening access to FDA-approved weight loss treatments as shifting market dynamics around GLP-1 drugs drive demand for more flexible and affordable options.

The company outlined a strategic shift in its U.S. weight loss business, emphasizing lower pricing, varied dosing, and multiple delivery formats.

It also confirmed a collaboration with Novo Nordisk A/S (NYSE:NVO) to support access to Wegovy injections and oral options.

As part of its platform upgrade, providers can now prescribe medications fulfilled by independent pharmacies, expanding treatment pathways for patients seeking GLP-1 therapies.

Read Also:

Also Read: Amazon GLP-1 Program Pressures Hims & Hers ...